Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received
approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug
Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference
Listed Drug (RLD), Deltasone Tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co. (Pharmacia).
According to IQVIA MAT December 2020 data, the US market for Prednisone Tablets USP, 10 mg and 20 mg is approximately US$ 60 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
The company has 127 cumulative ANDA filings with USFDA of which 98 ANDAs have been approved and 29 are pending approval.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
